… , Incorporated (NASDAQ:CYTK) Q2 2024 Earnings Conference Call August 8, 2024 … , he led business development at Celgene and held partner positions at … joining us on this Q2 earnings call today, an especially important …

… SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript April 24, 2024 … Evotec SE misses on earnings expectations. Reported EPS is $-0 … contribution were related to BMS’ Celgene programs and the successful delivery …

… 2024 Viatris Inc. misses on earnings expectations. Reported EPS is $0 … an important metric to reflect earnings growth and balanced capital … a measure of our expected earnings growth moving forward. Estimated … that from your time at Celgene. So just trying to …

… Corporation (NASDAQ:TWST) Q1 2024 Earnings Call Transcript February 2, 2024 … capacity has increased whether we Celgene stand our or Express. When …

… Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript November 14, 2023 … Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants … acquired after FDA approval by Celgene, while Bluebird wasn’t acquired …

… (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript November 14, 2023 … Bristol-Myers Squib formerly Celgene. His prior experience comprised … to issuing our quarterly earnings press release yesterday, we … discussed in our last earnings call, based upon enrollment …

… (NASDAQ:GERN) Q2 2023 Earnings Call Transcript August 3, 2023 … Geron Corporation misses on earnings expectations. Reported EPS is $- … Corporation Second Quarter 2023 Earnings Conference Call. I am … with Amgen, Novartis and Celgene, which of course is …

… Ltd. (NASDAQ:VEON) Q2 2023 Earnings Call Transcript August 3, 2023 … with the SEC. The earnings release and the earnings presentation, each of … to the sale of the Celgene [ph] operations. and has no …

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress ( …

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia,  with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025 …